

---

List of Contributors	xi
Preface	xix
Acknowledgments	xxi

## SECTION 1: Epidemiology

1. Epidemiology of bladder cancer	3
<i>Michael J Droller</i>	
2. Occupational risk factors	13
<i>Sarah A Felknor, George L Delclos</i>	
3. Familial bladder cancer	19
<i>Lambertus A Kiemeney</i>	
4. Genetic susceptibility to bladder cancer	27
<i>Aditi Hazra, Jian Gu, Xifeng Wu</i>	

## SECTION 2: Pathology

5. Urothelial carcinoma and its variants	39
<i>Antonio Lopez-Beltran, Liang Cheng</i>	
6. WHO/ISUP grading system	63
<i>Theresa Chan, Jonathan I Epstein</i>	
7. Urothelial bladder tumor pathology: contemporary consensus classification and diagnosis based on the World Health Organization (WHO) 1973 classification	71
<i>David G Bostwick, Rodolfo Montironi, Junqi Qian, Antonio Lopez-Beltran, Liang Cheng</i>	
8. Non-urothelial tumors	85
<i>David Grignon, Gail Bentley</i>	

9.	Gene discovery (overview) <i>Margaret Knowles</i>	95
10.	Molecular biology of bladder cancer: cell cycle alterations <i>Ben George, Ram H Datar, Richard J Cote</i>	107
11.	Cytogenetics of urothelial neoplasia <i>Pamela J Russell, Guido Sauter, Tzong-Tyng Hung, Frederick M Waldman</i>	123
12.	Gene microarrays <i>Torben F Orntoft</i>	137
13.	Molecular biology of invasive and metastatic urothelial cancer <i>Dan Theodorescu</i>	147
14.	Animal models of bladder cancer <i>Xue-Ru Wu, Tung-Tien Sun; David J McConkey, Marissa Shrader, Angela Papageorgiou</i>	157
15.	Animal models: naturally occurring canine urinary bladder cancer <i>Deborah W Knapp</i>	171

## SECTION 4: Diagnosis

16.	Cystoscopy <i>Alan M Nieder, Mark S Soloway</i>	179
17.	Florescence endoscopy <i>Martin Kriegmair</i>	187
18.	Imaging in the assessment of urinary bladder carcinoma <i>Barthold PH Schrier, J Alfred Witjes, Yoshifumi Narumi, Jelle Barentsz</i>	191
19.	Cytology and DNA ploidy <i>Ralph W DeVere White, Arline D Deitch</i>	207
20.	Voided urine markers <i>Vinata B Lokeshwar, Robert H Getzenberg</i>	211
21.	Staging <i>Atreya Dash, David P Wood Jr</i>	229
22.	Etiology and management of urothelial tumors of the renal pelvis and ureter <i>Guillermo Lima, Thomas Jarrett, Noel Clarke</i>	237
23.	Early detection for bladder cancer <i>George P Hemstreet III, Edward M Messing</i>	257

	urinary bladder	267
	<i>Michael J Droller</i>	
25.	Risk stratification of Ta, Tis, T1 cancer	281
	<i>Paula MJ Moonen, J Alfred Witjes</i>	
26.	Issues in staging of Ta, Tis, T1 bladder cancers	287
	<i>Sharon Sharir, Andrew J Evans, Mary K Gospodarowicz, Michael AS Jewett</i>	

## SECTION 5: Treatment

27.	Transurethral resection of bladder tumors	299
	<i>Harry W Herr</i>	
28.	Laser ablation and other technology	311
	<i>Jeffrey A Jones</i>	
29.	Perioperative instillation of chemotherapeutic drugs	329
	<i>Willem Oosterlinck, Richard J Sylvester</i>	
30.	The role of intravesical chemotherapy in the treatment of bladder cancer	335
	<i>S Bruce Malkowicz</i>	
31.	Intravesical chemotherapy of superficial bladder cancer: optimization and novel agents	341
	<i>Jessie L-S Au, M Guillaume Wientjes</i>	
32.	Intravesical immunotherapy: BCG	353
	<i>Lori A Pinke, Donald L Lamm</i>	
33.	Mode of action of BCG and rationale for combination immunotherapy	359
	<i>Andreas Böhle, Sven Brandau</i>	
34.	Marker tumor concept: ethical issues	367
	<i>Laurence B McCullough</i>	
35.	The use of the marker tumor concept in Ta, T1 bladder cancer: is it justified?	371
	<i>Adrian PM van der Meijden</i>	
36.	Photodynamic therapy	375
	<i>Michael J Manyak, Unyime O Nseyo</i>	
37.	G3T1 bladder carcinoma	387
	<i>Vito Pansadoro, Paolo Emiliozzi</i>	
38.	What to do when BCG fails	397
	<i>Guido Dalbagni</i>	

39.	Chemoprevention of superficial bladder cancer <i>Anita L Sabichi, Scott M Lippman</i>	403
40.	Surrogate endpoint biomarkers <i>Robert W Veltri</i>	411
41.	Follow-up strategies in superficial bladder cancer <i>Juan Palou, José Segarra</i>	421

## SECTION 6: T2-4

42.	The natural history of invasive bladder cancer <i>George R Prout Jr</i>	429
43.	Selection and perioperative management of patients undergoing radical cystectomy and urinary reconstruction <i>Melissa R Kaufman, Joseph A Smith Jr</i>	433
44.	Radical cystectomy—technique and outcomes <i>John P Stein, Donald G Skinner</i>	445
45.	Cystectomy in the female <i>Aristotelis G Anastasiadis, Susan Feyerabend, Markus A Kuczyk, Arnulf Stenzl</i>	471
46.	Nerve-sparing radical cystectomy <i>Marc S Chuang, Gary D Steinberg, Mark Schoenberg</i>	479
47.	Laparoscopic radical cystectomy and urinary diversion <i>Inderbir S Gill, Ingolf Tuerk</i>	487
48.	Role of extended pelvic lymphadenectomy <i>Bernard H Bochner, Seth P Lerner</i>	499
49.	Role of sentinel node detection <i>Per-Uno Malmström, Amir Sherif</i>	507
50.	Management of the urethra in the cystectomy patient <i>Hendrik Van Poppel</i>	515
51.	Role of radical cystectomy in patients with unresectable and/or locoregionally metastatic bladder cancer <i>S Machele Donat</i>	525

## SECTION 7: Primary bladder sparing therapy

52.	Radical TURBT <i>Eduardo Solsona</i>	535
53.	Partial cystectomy <i>Yair Lotan, David A Swanson, Arthur J Sagalowsky</i>	543

54.	Optimal radiotherapy for bladder cancer	551
	<i>Michael F Milosevic, Robert Bristow, Mary K Gospodarowicz</i>	
55.	Trimodality therapy in the management of muscle-invasive bladder cancer: a selective organ-preserving approach	569
	<i>John J Coen, Anthony L Zietman, Donald S Kaufman, Niall M Heney, Alex F Althausen, William U Shipley</i>	

## SECTION 8: Urinary tract reconstruction

56.	Orthotopic neobladder	581
	<i>Richard E Hautmann</i>	
57.	Continent cutaneous diversion	595
	<i>Christoph Wiesner, Randall G Rowland, Joachim W Thüroff</i>	
58.	Noncontinent urinary diversion	607
	<i>Wiking Månsson, Frederik Liedberg, Roland Dahlem, Margit Fisch</i>	
59.	Metabolic aspects of diversion	615
	<i>Robert D Mills, Urs E Studer</i>	
60.	Psychosocial and quality-of-life issues	631
	<i>Åsa Månsson, Eila C Skinner</i>	
61.	Tissue engineering of the bladder	637
	<i>Gilad E Amiel, Anthony Atala, Donald P Griffith</i>	

## SECTION 9: Treatment of regionally advanced and metastatic bladder cancer

62.	Clinical trial design	647
	<i>Richard J Sylvester, Takuhiro Yamaguchi</i>	
63.	Neo-adjuvant chemotherapy in the treatment of muscle-invasive bladder cancer	657
	<i>Cora N Sternberg</i>	
64.	Adjuvant chemotherapy for invasive bladder cancer	665
	<i>James O Jin, Michelle Boyar, Daniel P Petrylak, Walter M Stadler</i>	
65.	Treatment of metastatic cancer	671
	<i>Avishay Sella, Joaqim Bellmunt</i>	
66.	Special considerations in the elderly patient	683
	<i>Gary R MacVicar, Maha Hussain</i>	

## SECTION 10: Novel and emerging therapy

- |     |  |     |
|-----|--|-----|
| 67. | Targeted therapy for bladder cancer                                    | 695 |
|     | <i>Wassim Kassouf, Bernard H Bochner, Colin P Dinney</i>               |     |
| 68. | Bladder cancer gene therapy  | 711 |
|     | <i>Zhiping Wang, William Benedict, Seth P Lerner, Ronald Rodriguez</i> |     |

## SECTION 11: Treatment of non-TCC

- |     |   |     |
|-----|---|-----|
| 69. | Treatment of non-TCC adenocarcinoma/sarcoma | 723 |
|     | <i>Sami Arap, Marco A Arap</i>              |     |
| 70. | Treatment of squamous cell carcinoma        | 729 |
|     | <i>Hassan Abol-Enein, Mohamed A Ghoneim</i> |     |
| 71. | Pediatric bladder tumours                   | 735 |
|     | <i>Fernando A Ferrer, Michael Ritchey</i>   |     |

## SECTION 12: Ancillary

- |     |  |     |
|-----|--|-----|
| 72. | Bladder cancer internet resources                  | 751 |
|     | <i>A Karim Kader, Laurence Klotz</i>               |     |
| 73. | Support groups                                     | 755 |
|     | <i>Mary Ellen Haisfield-Wolfe</i>                  |     |
| 74. | Education and counseling of the cystectomy patient | 759 |
|     | <i>Joanne Walker</i>                               |     |

- |       |     |
|-------|-----|
| Index | 763 |
|-------|-----|